Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934
February
19, 2009
Date of
Report (Date of earliest event reported)
WATSON
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
001-13305
|
95-3872914
|
(State
or other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
Number)
|
311
Bonnie Circle
Corona,
California
(Address
of principal executive offices)
|
|
92880
(Zip
Code)
|
(951)
493-5300
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02 Results
of Operations and Financial Condition.
On
February 19, 2009, Watson Pharmaceuticals, Inc. (the “Company”) issued a press
release reporting the financial results of the Company for the fourth quarter
and full year ended December 31, 2008, and providing a forecast of certain
estimated financial metrics for 2009. A copy of the Company’s press
release is attached to this report as Exhibit 99.1 and incorporated herein by
reference.
In its
press release, the Company included non-GAAP financial measures, as defined in
Regulation G promulgated by the U. S. Securities and Exchange
Commission. The Company believes that its inclusion of non-GAAP
financial measures provides useful supplementary information to and facilitates
analysis by investors in evaluating the Company’s performance and
trends. The Company uses both GAAP financial measures and the
disclosed non-GAAP financial measures internally to evaluate and manage the
Company’s operations and to better understand its business. These
non-GAAP financial measures are in addition to, not a substitute for, or
superior to, measures of financial performance prepared in accordance with
GAAP.
The
information in this report (including the exhibit) is furnished pursuant to Item
2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”), nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as shall be expressly set forth by specific reference in
such filing.
Item
9.01 Financial
Statements and Exhibits.
d. Exhibits:
|
99.1
|
Press
Release titled “Watson Pharmaceuticals Reports Fourth Quarter and Full
Year 2008 Results; Provides 2009 Outlook” dated February 19,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: February
19, 2009
|
WATSON
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Mark W. Durand
|
|
|
Mark
W. Durand
|
|
|
Senior
Vice President – Chief Financial Officer
|
|
|
Principal
Financial Officer
|
EXHIBIT
INDEX
Exhibit
No.
|
|
Description
|
99.1
|
|
Press
Release titled “Watson Pharmaceuticals Reports Fourth Quarter and Full
Year 2008 Results; Provides 2009 Outlook” dated February 19,
2009.
|